Perkins Capital Management Inc. Sells 4,000 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Perkins Capital Management Inc. lessened its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 24.7% during the 4th quarter, Holdings Channel reports. The firm owned 12,200 shares of the company’s stock after selling 4,000 shares during the quarter. Perkins Capital Management Inc.’s holdings in scPharmaceuticals were worth $43,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in SCPH. Thrivent Financial for Lutherans grew its stake in scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after buying an additional 14,866 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of scPharmaceuticals during the third quarter worth $57,000. BNP Paribas Financial Markets increased its stake in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after buying an additional 3,101 shares in the last quarter. Rubric Capital Management LP raised its holdings in shares of scPharmaceuticals by 35.5% in the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after buying an additional 1,250,000 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in scPharmaceuticals by 135.0% during the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock worth $77,000 after buying an additional 9,752 shares in the last quarter. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Price Performance

Shares of SCPH stock opened at $3.00 on Monday. The firm has a market cap of $150.85 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. scPharmaceuticals Inc. has a 12 month low of $2.75 and a 12 month high of $5.65. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.77.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The company had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. Research analysts expect that scPharmaceuticals Inc. will post -1.53 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on SCPH. Maxim Group lowered their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.